Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
In preclinical experiments [212Pb] VMT01 demonstrated efficacy via direct cell killing at high radiation doses and through immunostimulatory low-dose induction of immune-mediated cell death.Perspective Therapeutics, Inc. (NYSE: CATX) is down 13% at $11.53 at last check Friday.
赛诺菲安万特公司（纽交所：CATX）周五最新数据显示下跌13%，报11.53美元。
The downtrend comes as initial results from its study of [212Pb]VMT01 are set to be presented to the International Congress of the Society for Melanoma Research.
这种下行趋势发生在其[212Pb]VMT01研究的初步结果即将提交给国际黑色素瘤研究学会大会的时候。
VMT01 is a MC1R-targeted radiopharmaceutical therapy (RPT) that can be radiolabeled with either 203Pb for patient selection and dosimetry assessments or 212Pb for alpha particle therapy.
VMT01 是一种MC1R靶向的放射性药物疗法（RPT），可以用203Pb进行患者选择和剂量评估，也可以用212Pb进行α粒子疗法。
In preclinical experiments [212Pb] VMT01 demonstrated efficacy via direct cell killing at high radiation doses and through immunostimulatory low-dose induction of immune-mediated cell death.
在临床前实验中，[212Pb] VMT01 在高辐射剂量下通过直接击杀细胞和通过免疫刺激低剂量诱导免疫介导的细胞死亡展现出疗效。
Efficacy was augmented by immune checkpoint inhibitors (ICIs).
免疫检查点抑制剂（ICIs）增强了疗效。
Three patients were enrolled in Cohort 1, while seven were enrolled in Cohort 2.
第一队有三名患者，而第二队有七名患者参加。
Patients in each cohort received a median of five prior lines of systematic therapy.
每个队的患者平均接受了五种先前系统治疗。
- No dose-limiting toxicities were observed among any patients, and no adverse events led to treatment discontinuation. Treatment-emergent adverse events (TEAEs) were mostly Grades 1 and 2; there were no Grade 4 or 5 TEAEs.
- No renal toxicities have been reported to date.
- All patients in Cohort 1 completed three treatments, with one patient experiencing a RECIST version 1.1 objective response and two patients experiencing stable disease at nine and 11 months from the start of treatment, respectively.
- In Cohort 2, patients progressed after either the first cycle (3 patients) or the second cycle (4 patients).
- 在任何患者中未观察到剂量限制性毒性，并且没有不良事件导致治疗中止。治疗相关的不良事件（TEAEs）主要是1级和2级；没有4级或5级的TEAEs。
- 到目前为止尚未报告肾毒性。
- 所有第1队患者完成了三次治疗，其中一名患者在治疗开始后九个月和十一个月分别获得了RECISt版本1.1的客观治疗反应，另外两名患者保持疾病稳定。
- 在第2队中，患者在第一周期（3名患者）或第二周期（4名患者）后出现了进展。
The Safety Monitoring Committee (SMC) has reviewed these findings. The SMC recommended exploring a lower dose level of 1.5 mCi per dose, which is lower than the dose administered in Cohort 1, both as a single agent and combined with the anti-PD-1 antibody, Bristol Myers Squibb & Co (NYSE:BMY) Opdivo (nivolumab).
安全监测委员会（SMC）已经审查了这些发现。SMC建议探索每剂1.5 mCi的更低剂量水平，该剂量低于在第1队单药和与抗PD-1抗体Bristol Myers Squibb& Co（纽交所:BMY）Opdivo（尼伐替尼）联合使用时给予的剂量。
The SMC recommendation would allow for the monotherapy and combination cohorts to proceed concurrently.
SMC的建议将允许单独治疗和联合队同时进行。
An amendment to further explore lower dose levels for monotherapy is planned. The combination cohort at 1.5 mCi per dose with nivolumab is active and now open for enrollment.
计划修订以进一步探索单药更低的剂量水平。每剂1.5 mCi的联合队与尼伐替尼目前已开始招募。
- World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice.
- 世界第三大场外交易参与者赛诺菲安万特（Sanofi）的消费健康部门即将与Clayton Dubilier & Rice达成价值160亿美元的交易。
